Literature DB >> 14727169

Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

Bernd Kasper1, Christoph Harter, Julia Meissner, Frauke Bellos, Fatime Krasniqi, Anthony D Ho, Gerlinde Egerer.   

Abstract

We report about a case of advanced Ewing sarcoma in a 30-year-old woman. Initial treatment was started according to the Euro-Ewing 99 protocol. During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus. Because of cerebral toxicity, the following chemotherapies went without ifosfamide. During final radiotherapy multiple lung metastasis were diagnosed. After two cycles of chemotherapy with cyclophosphamide and topotecan (no response), left thoracotomy, and palliative pneumectomy, the patient was transferred to our ward for further treatment. Undergoing two cycles of chemotherapy with ifosfamide 4 g/m(2) intravenously for 3 consecutive days followed by high-dose chemotherapy (HDCT) according to the ICE-regimen (ifosfamide 2 g/m(2), carboplatin 200 mg/m(2), and etoposide 2 x 100 mg/m(2) intravenously for 6 consecutive days), and peripheral blood stem cell transplantation (PBSCT), complete remission was achieved. Under preventive therapy with methylene blue, thiamin, and glucose 5% infusions, no encephalopathy occurred.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727169     DOI: 10.1007/s00520-003-0573-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  [Glucose infusions--a possible effective therapeutic option in ifosfamide-induced encephalopathy].

Authors:  O Kellner; W Dempke; H J Schmoll
Journal:  Dtsch Med Wochenschr       Date:  1999-09-17       Impact factor: 0.628

2.  Pharmacokinetics and organ distribution of intravenous and oral methylene blue.

Authors:  C Peter; D Hongwan; A Küpfer; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  2000-06       Impact factor: 2.953

3.  Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.

Authors:  A Küpfer; C Aeschlimann; B Wermuth; T Cerny
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

4.  Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.

Authors:  C Aeschlimann; A Küpfer; H Schefer; T Cerny
Journal:  Drug Metab Dispos       Date:  1998-09       Impact factor: 3.922

5.  [Successful treatment with methylene blue of ifosfamide-induced central nervous system effects].

Authors:  M Demandt; H Wandt
Journal:  Dtsch Med Wochenschr       Date:  1996-04-26       Impact factor: 0.628

6.  Encephalopathy associated with ifosphamide/mesna therapy.

Authors:  C A Meanwell; A E Blake; T N Latief; G Blackledge; J J Mould; D R Blake; I C Shaw; L Honigsberger; D Spooner; A C Williams
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

7.  Methylene blue for ifosfamide-associated encephalopathy.

Authors:  G B Zulian; E Tullen; B Maton
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.

Authors:  J Y Blay; D Bouhour; I Ray-Coquard; C Dumontet; T Philip; P Biron
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

9.  Ifosfamide-induced encephalopathy.

Authors:  Ana M Gonzalez-Angulo; Jennifer A Orzano; Enrique Davila
Journal:  South Med J       Date:  2002-10       Impact factor: 0.954

10.  Ifosfamide causes a diazepam-sensitive encephalopathy.

Authors:  N A Simonian; F G Gilliam; K H Chiappa
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.